Critical Care Research
  • Welcome
  • Training and getting involved
  • Critical care research team
  • Currently recruiting
    • A2B
    • ADAPT-Sepsis
    • BLING III
    • EFFORT
    • GenOMICC
    • HEMOTION
    • ISARIC
    • PIM-COVID
    • PHIND
    • REMAP-CAP
    • SIGNET
      • SIGNET cascade training
    • SOS
    • STRESS-L
    • TEAM
    • UK-ROX
    • VITDALIZE
  • Upcoming studies
    • MARCH
    • MaST
Powered by GitBook
On this page
  • PICO Question
  • Recruitment
  • Details

Was this helpful?

  1. Currently recruiting

BLING III

Beta-lactam antibiotics infusion group study

PreviousADAPT-SepsisNextEFFORT

Last updated 3 years ago

Was this helpful?

PICO Question

  • Population: ICU patients receiving Tazocin or meropenem for sepsis

  • Interventions: Continuous infusions of beta-lactam antibiotics

  • Comparison: Usual care

  • Outcomes: 90-day mortality, unit-acquired infections

Recruitment

Inclusion criteria

Exclusion criteria

  • Documented/strong suspicion of infection

  • Expected to be in ICU >24h

  • Started Tazocin or meropenem

  • ≥1 organ dysfunction in previous 24h

  • Aged < 18 years

  • Recieved Tazocin or meropenem for >24h during current infection

  • Pregnant

  • Tazocin/meropenem allergy

  • Need for RRT

  • Planned withdrawal within 48h

  • Previously enrolled in this trial.

Details

  • Principle investigator: Dan Harvey

  • Trainee-lead:

  • DREEAM: Martin Dent

Website:

https://www.georgeinstitute.org/projects/beta-lactam-antibiotics-infusion-group-study-bling-iii